<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="There is an unmet public health need for a universal" exact="influenza" post="vaccine (UIV) to provide broad and durable protection from"/>
 <result pre="influenza vaccine (UIV) to provide broad and durable protection from" exact="influenza" post="virus infections. The identification of broadly protective antibodies and"/>
 <result pre="of broadly protective antibodies and cross-reactive T cells directed to" exact="influenza" post="viral targets present a promising prospect for the development"/>
 <result pre="trials. Mucosal immune responses and cross-reactive T cell immunity across" exact="influenza" post="A and B viruses intrinsic to live attenuated influenza"/>
 <result pre="across influenza A and B viruses intrinsic to live attenuated" exact="influenza" post="vaccine (LAIV) have emerged as essential features to be"/>
 <result pre="protection. Preexisting immunity in humans established by prior exposure to" exact="influenza" post="viruses may affect the hierarchy and magnitude of immune"/>
 <result pre="the hierarchy and magnitude of immune responses elicited by an" exact="influenza" post="vaccine, limiting the interpretation of preclinical data based on"/>
 <result pre="a wide spectrum of protection, and safety relevant to UIVs." exact="influenza" post="virus universal influenza vaccine cross-protection HA stalk M2e T"/>
 <result pre="of protection, and safety relevant to UIVs. influenza virus universal" exact="influenza" post="vaccine cross-protection HA stalk M2e T cell live attenuated"/>
 <result pre="influenza vaccine cross-protection HA stalk M2e T cell live attenuated" exact="influenza" post="vaccine Funding National Research Foundation of Korea10.13039/5011000037252018M3A9H40793582018R1D1A1B07048881 Korea Food"/>
 <result pre="season and, thus, c represents the primary targets of seasonal" exact="influenza" post="vaccines (Sridhar et al., 2015). In addition to seasonal"/>
 <result pre="vaccines (Sridhar et al., 2015). In addition to seasonal epidemics," exact="influenza" post="viruses have caused pandemics at the intervals of ~10–40"/>
 <result pre="2016). While vaccination remains the most cost-effective measure to prevent" exact="influenza" post="virus infections, antigenic drift in the surface antigens allows"/>
 <result pre="is unpredictable, posing a serious challenge to the management of" exact="influenza" post="outbreak. Based on the amino acid sequences of HAs,"/>
 <result pre="influenza outbreak. Based on the amino acid sequences of HAs," exact="influenza" post="A viruses (IAVs) are divided into two phylogenetic groups."/>
 <result pre="Victoria-like lineages. Influenza C viruses (ICVs) generally cause a mild" exact="respiratory disease" post="in humans and do not cause epidemics (Dykes et"/>
 <result pre="and do not cause epidemics (Dykes et al., 1980). Contemporary" exact="influenza" post="epidemics are caused by the H1N1 and H3N2 of"/>
 <result pre="two lineages of the IBVs, dictating trivalent (TIV) or quadrivalent" exact="influenza" post="vaccine (QIV) containing two IAV antigens and one or"/>
 <result pre="Figure 1 Phylogenetic trees representing HA and NA diversity among" exact="influenza" post="viruses. The 18 subtypes of HAs of IAV are"/>
 <result pre="trees were constructed based on amino acid sequence comparisons among" exact="influenza" post="viruses. Multiple alignments were carried out using the representative"/>
 <result pre="have been undertaken on the pursuit of developing a universal" exact="influenza" post="vaccine (UIV) (Paules et al., 2017). The induction of"/>
 <result pre="While these vaccines showed broader cross-protection than the classical inactivated" exact="influenza" post="vaccines (IIVs), their protection potency was weak. They provided"/>
 <result pre="(B) Cytotoxic T lymphocyte (CTL) recognizing the conserved epitopes of" exact="influenza" post="internal proteins such as NP, M1, or PB1 has"/>
 <result pre="HA stalk in animals and humans with prior exposure to" exact="influenza" post="viruses. Some of these antibodies show extremely broad specificity,"/>
 <result pre="immunity have emerged as potential correlates of broad protection against" exact="influenza" post="infections (Krammer and Palese, 2015), the exact molecular mechanisms"/>
 <result pre="imprinting or antigenic sin-like phenomenon) shaped by prior exposure to" exact="influenza" post="viruses affects the magnitude, hierarchy, and sustainability of antibody"/>
 <result pre="that provides durable and broad protection against multiple strains of" exact="influenza" post="virus, the definition of the &quot;universality�? of UIV is"/>
 <result pre="reasonable UIV should be at least 75% effective against symptomatic" exact="influenza" post="virus infection caused by group 1 and group 2"/>
 <result pre="criteria for a UIV. NIAID WHO BMGF Consensus Breadth All" exact="influenza" post="A viruses (influenza B protection would be the second"/>
 <result pre="viruses (influenza B protection would be the second target) All" exact="influenza" post="A viruses All influenza A and B viruses All"/>
 <result pre="would be the second target) All influenza A viruses All" exact="influenza" post="A and B viruses All influenza A viruses Efficacy"/>
 <result pre="influenza A viruses All influenza A and B viruses All" exact="influenza" post="A viruses Efficacy At least 75% effective against symptomatic"/>
 <result pre="influenza A viruses Efficacy At least 75% effective against symptomatic" exact="influenza" post="infection Better than that of current seasonal influenza vaccine"/>
 <result pre="against symptomatic influenza infection Better than that of current seasonal" exact="influenza" post="vaccine At least 70% effective against symptomatic influenza infection"/>
 <result pre="current seasonal influenza vaccine At least 70% effective against symptomatic" exact="influenza" post="infection At least 70% effective Target population All age"/>
 <result pre="World Health Organization (https://apps.who.int/iris/bitstream/handle/10665/258767/9789241512466-eng.pdf; https://jsessionid=37D9E056C3EA58A90EE237432AA7D65F?sequence=1). Figure 3 Protection breadth of" exact="influenza" post="vaccines ranging from strain-specific protection to pan-influenza universal protection."/>
 <result pre="from strain-specific protection to pan-influenza universal protection. Currently licensed seasonal" exact="influenza" post="vaccine provides only strain-specific protection against well-matched strains. Recently,"/>
 <result pre="the knowledge gaps in developing a UIV; (1) understanding of" exact="influenza" post="transmission, natural history, and viral pathogenesis, (2) characterization of"/>
 <result pre="quality, depending on the vaccine type used and the target" exact="influenza" post="virus tested. For instance, while the protection potency of"/>
 <result pre="assay or microneutralization assay is the gold standard for seasonal" exact="influenza" post="vaccines (Ohmit et al., 2011). However, the assay cannot"/>
 <result pre="simply to reflect the cross-protection by a UIV against heterologous/heterosubtypic" exact="influenza" post="viruses. Therefore, it is essential to develop mechanistically distinct"/>
 <result pre="determination of the precise protection mechanisms of immune response against" exact="influenza" post="viruses. Influenza HA recognizes sialic acid on the cellular"/>
 <result pre="the conserved regions have shown an exceptional breadth, inhibiting divergent" exact="influenza" post="viruses (Chen et al., 2018). In addition to the"/>
 <result pre="M2e on their surface. It has been shown that the" exact="hepatitis" post="B virus core (HBc) protein fused with M2e self-assembled"/>
 <result pre="enveloped VLPs displayed M2e in a membrane-anchored manner by combining" exact="influenza" post="matrix protein and transmembrane (TM) domain of HA fused"/>
 <result pre="M2e. The Sf9 insect cells infected with baculoviral vectors expressing" exact="influenza" post="M1 and M2e-TM of influenza HA produced influenza VLPs"/>
 <result pre="infected with baculoviral vectors expressing influenza M1 and M2e-TM of" exact="influenza" post="HA produced influenza VLPs displaying much higher levels of"/>
 <result pre="vectors expressing influenza M1 and M2e-TM of influenza HA produced" exact="influenza" post="VLPs displaying much higher levels of M2e than the"/>
 <result pre="vaccine antigen and the low abundance of M2 proteins on" exact="influenza" post="virions and infected cells. From the clinical and practical"/>
 <result pre="a stand-alone UIV. Consequently, M2e antigen was combined with other" exact="influenza" post="viral antigens (mostly HA) or supplemented with strain-specific vaccines,"/>
 <result pre="and broader cross-protection. For instance, several studies combined M2e with" exact="influenza" post="HA head or stalk domain to elicit broadly protective"/>
 <result pre="or stalk domain to elicit broadly protective immunity against heterologous" exact="influenza" post="infections with various vaccine platforms including nanoparticles, recombinant proteins,"/>
 <result pre="with various vaccine platforms including nanoparticles, recombinant proteins, and recombinant" exact="influenza" post="viruses (Guo et al., 2017; Bernasconi et al., 2018;"/>
 <result pre="activity of the stalk antibodies may lead to neutralization of" exact="influenza" post="viruses, although the neutralizing potency is weaker than head"/>
 <result pre="paved the way to increase the breadth of protection against" exact="influenza" post="viruses. Figure 5 HA stalk-based approaches. Influenza HA comprises"/>
 <result pre="function of stalk-reactive antibodies is membrane fusion inhibition. Following the" exact="influenza" post="virus entry into the cells via endocytosis, a pH-dependent"/>
 <result pre="ADCP, by which macrophages or neutrophils recognize and engulf antibody-bound" exact="influenza" post="viral particles or infected cells (Ana-Sosa-Batiz et al., 2016)."/>
 <result pre="infection. Overall, the stalk antibodies confer a broad protection from" exact="influenza" post="virus infection through multiple mechanisms affecting both HA and"/>
 <result pre="affecting both HA and NA throughout the infection cycle of" exact="influenza" post="virus. HA Stalk-Based Vaccine Constructs The first reported HA"/>
 <result pre="genetically engineered viruses of the wild type or live attenuated" exact="influenza" post="viruses (Krammer et al., 2013; Isakova-Sivak et al., 2018)."/>
 <result pre="and rather than the stalk antibodies (see section Live attenuated" exact="influenza" post="vaccine as an alternative strategy below). This observation in"/>
 <result pre="2013). Similarly, the HA subunit vaccine resulted in vaccine-associated enhanced" exact="respiratory disease" post="(VAERD) in pigs after heterologous challenge (Gauger et al.,"/>
 <result pre="the stalk flexibility and membrane fusion kinetics, resulting in enhanced" exact="respiratory disease" post="in a mouse model (Winarski et al., 2019). These"/>
 <result pre="(Ng et al., 2019). Stalk Variability Although conserved among the" exact="influenza" post="viruses, the HA stalk is not antigenically identical, showing"/>
 <result pre="responses (Kirkpatrick et al., 2018). Several studies have isolated mutant" exact="influenza" post="viruses showing resistance to stalk antibodies (Ekiert et al.,"/>
 <result pre="importantly, most humans have a diverse history of exposure to" exact="influenza" post="antigens, by natural infection, or vaccination. The established immune"/>
 <result pre="bind to the RBS in HA and neutralize multiple H1N1" exact="influenza" post="strains (Whittle et al., 2011). A caveat is that"/>
 <result pre="to recognize conserved region in the RBS and neutralize multiple" exact="influenza" post="viruses (Krause et al., 2011, 2012; Ekiert et al.,"/>
 <result pre="conserved regions located in HA head domain and neutralized multiple" exact="influenza" post="viruses without detectable HI activity (Iba et al., 2014;"/>
 <result pre="induced stronger immune response and provided better protection against heterologous" exact="influenza" post="viruses, as compared to natural wild type HA antigen."/>
 <result pre="The COBRA strategy was tested against H1N1, H3N2, and H5N1" exact="influenza" post="viruses, and demonstrated broad protection within a subtype (Giles"/>
 <result pre="II transmembrane glycoprotein and the second major surface protein of" exact="influenza" post="viruses. The role of NA in influenza infection cycle"/>
 <result pre="surface protein of influenza viruses. The role of NA in" exact="influenza" post="infection cycle is classically known as an expedited release"/>
 <result pre="stage of infection. At the entry site in the mucus," exact="influenza" post="virus meets mucosal defense proteins such as mucins that"/>
 <result pre="cooperates with HA to enable crawling and gliding motions of" exact="influenza" post="virus on cell surface to enhance viral entry into"/>
 <result pre="NA antibodies may represent an important means of protection against" exact="influenza" post="viruses. NA Antibodies as Important Correlate of Protection The"/>
 <result pre="shift in HA, but NA remained close to the previous" exact="influenza" post="A/H2N2 viruses (Schulman and Kilbourne, 1969). Notably, it has"/>
 <result pre="However, NA has been largely ignored in the formulation of" exact="influenza" post="vaccines due to the general beliefs that NA antibodies"/>
 <result pre="functional NA antibodies has rendered the NA forgotten antigens in" exact="influenza" post="vaccines for decades (Eichelberger and Monto, 2019). Most of"/>
 <result pre="on the induction of HA antibodies, both in trivalent/quadrivalent seasonal" exact="influenza" post="vaccines and in the recent UIV candidates. However, it"/>
 <result pre="vaccination-induced or preexisting NAI antibody levels and decreased frequency of" exact="influenza" post="infection and illness (Couch et al., 2013; Monto et"/>
 <result pre="identified NAI monoclonal antibodies that show protective effects against heterologous" exact="influenza" post="infection. The breadth of NAI antibodies varied from subtype-specific"/>
 <result pre="2013a,b; Wan et al., 2013). Recently, it was reported that" exact="influenza" post="infection in humans induces a variety of broadly reactive"/>
 <result pre="the importance of NA-immunity in protection against homologous and heterologous" exact="influenza" post="infections is clearly established, only a few literatures have"/>
 <result pre="However, co-administration of H7 HA and N3 NA in modified" exact="vaccinia virus" post="Ankara (MVA) vectors did not demonstrate enhanced protection efficacy"/>
 <result pre="in favor of HA over NA, when presented in an" exact="influenza" post="virion, is already well-documented (Johansson et al., 1987), and"/>
 <result pre="of NA-based vaccines in animal models. Considering the repertoire of" exact="influenza" post="viruses infecting humans and animals (including N1, N2, N3,"/>
 <result pre="Against Influenza B Viruses Besides IAVs, ~25% of all human" exact="influenza" post="virus infections in each epidemic season is caused by"/>
 <result pre="and Yamagata-like lineages (Ambrose and Levin, 2012). The current seasonal" exact="influenza" post="vaccine is prepared in a trivalent or quadrivalent formulation,"/>
 <result pre="broadly protective antibodies binding to head or stalk domain of" exact="influenza" post="B HA have been isolated in humans. Overall, these"/>
 <result pre="acknowledged as a potential immune correlate of broad protection against" exact="influenza" post="infections (Sridhar, 2016; Clemens et al., 2018). T cell"/>
 <result pre="cell immunity may not provide sterilizing or neutralizing immunity against" exact="influenza" post="viruses but improves the standard of care by reducing"/>
 <result pre="critical to provide a truly universal protection against highly variable" exact="influenza" post="viruses. The influenza-specific T cell immunity is known to"/>
 <result pre="that inducing T cell immunity directed to internal proteins of" exact="influenza" post="virus may provide a basis of developing T cell-based"/>
 <result pre="epitopes but also T cell epitopes encompassing both types of" exact="influenza" post="viruses. The fusion peptide in HA stalk contains a"/>
 <result pre="cells in humans that could be induced by exposure to" exact="influenza" post="viruses, but also presents the prospect of designing a"/>
 <result pre="cells were not induced in HHD-A2 mouse model despite multiple" exact="influenza" post="infections or vaccinations and the protective role of the"/>
 <result pre="al., 2014; Folegatti et al., 2019). The baculovirus VLPs carrying" exact="influenza" post="HA/NA and M1 offered cross-protection where T cells played"/>
 <result pre="fact, the first report on DNA vaccines was targeted to" exact="influenza" post="virus (Cohen, 1993; Ulmer et al., 1993), but initial"/>
 <result pre="been made to improve the efficacy of DNA vaccine against" exact="influenza" post="virus, encompassing rational design of antigens and expression vectors"/>
 <result pre="in humans since 2003 and is proven effective in preventing" exact="influenza" post="infections (Mohn et al., 2018). The protection of LAIV"/>
 <result pre="LAIV are critical for broad protection against heterologous and heterosubtypic" exact="influenza" post="infections in animal models (Cheng et al., 2013; Jang"/>
 <result pre="investigate if the cross-protection could be extended to group 2" exact="influenza" post="viruses such as H3 or H7 strains. Besides the"/>
 <result pre="the LAIV presents a remarkable prospect for a broadly protective" exact="influenza" post="vaccine, several important issues need to be addressed for"/>
 <result pre="mutations among various internal genes and proven safe as seasonal" exact="influenza" post="vaccines (especially for A/Ann Arbor strain as the master"/>
 <result pre="strains. During the past century, H1N1 and H3N2 subtypes of" exact="influenza" post="A viruses were the most prevalent strains in humans,"/>
 <result pre="of H2N2 during 1957–1968 (Kilbourne, 2006) (Figure 6). Accordingly, seasonal" exact="influenza" post="vaccines are recommended to include H1N1 and H3N2 vaccine"/>
 <result pre="nature of strain itself does not really matter for seasonal" exact="influenza" post="vaccine, for which strain-specific immunity is focused on the"/>
 <result pre="T cell immunity as an essential factor for truly universal" exact="influenza" post="protection for internal proteins). It is likely that human"/>
 <result pre="protection by a UIV; Figure 3). Figure 6 Co-evolution of" exact="influenza" post="viruses and influenza vaccines. Within the past century, there"/>
 <result pre="UIV; Figure 3). Figure 6 Co-evolution of influenza viruses and" exact="influenza" post="vaccines. Within the past century, there were four influenza"/>
 <result pre="and influenza vaccines. Within the past century, there were four" exact="influenza" post="pandemics; 1918 Spanish flu (H1N1), 1957 Asian flu (H2N2),"/>
 <result pre="Krewski, 2016). The 1918 Spanish flu (H1N1) evolved into seasonal" exact="influenza" post="strain and had circulated for ~40 years until the"/>
 <result pre="Hong Kong flu (H3N2) has circulated until now as seasonal" exact="influenza" post="strains. In 1977, H1N1 strain reemerged and was replaced"/>
 <result pre="by the 2009 swine flu (H1N1), which evolved into seasonal" exact="influenza" post="strains circulating until now. Thus, H1N1 and H3N2 strains"/>
 <result pre="necessitates the incorporation of Victoria-like and Yamagata-like lineages in seasonal" exact="influenza" post="vaccines. This leads us to raise a possibility of"/>
 <result pre="leads us to raise a possibility of using an ancestral" exact="influenza" post="B strain (such as B/Lee/40) before divergence into two"/>
 <result pre="internal proteins. Alternatively, vaccination with LAIV carrying HA from non-human" exact="influenza" post="viruses such as H5 or H9 may be effective"/>
 <result pre="use infection-competent but replication-defective viruses. For instance, the M2 knock-out" exact="influenza" post="virus (M2SR) rescued from M2-producing cells is able to"/>
 <result pre="and to provide broad protection against both homologous and heterologous" exact="influenza" post="virus challenge in mice and ferrets (Sarawar et al.,"/>
 <result pre="al., 2017, 2018). A conceptually similar to M2SR, PB2 knock-out" exact="influenza" post="virus could be produced in PB2-expressing cells as a"/>
 <result pre="The protection efficacy of PB2-KO vaccine was tested against diverse" exact="influenza" post="strains in mice (Victor et al., 2012; Uraki et"/>
 <result pre="2012; Uraki et al., 2013; Ui et al., 2017). Pseudotyped" exact="influenza" post="A virus also presents a similar replication-incompetent virus approach."/>
 <result pre="virus also presents a similar replication-incompetent virus approach. The pseudotyped" exact="influenza" post="virus lacking HA produced in HA-expressing cells can infect"/>
 <result pre="that the vaccination of mice and ferrets with the pseudotyped" exact="influenza" post="virus generated a vigorous T cell response and reduced"/>
 <result pre="loads and weight loss after challenge with homologous and heterologous" exact="influenza" post="viruses (Powell et al., 2012; Baz et al., 2015)."/>
 <result pre="to conventional vaccine platforms against various infectious diseases including the" exact="influenza" post="virus (Pardi et al., 2018a). Initially, the mRNA vaccines"/>
 <result pre="antibody responses were associated with protection against homologous and heterologous" exact="influenza" post="virus infection in mice (Pardi et al., 2018b), depicting"/>
 <result pre="Preexisting immunity or immunologic imprinting, established by prior exposure to" exact="influenza" post="by infection or vaccination, may influence or thwart the"/>
 <result pre="evasion and provide a truly universal protection against the ever-changing" exact="influenza" post="viruses. Author Contributions BS designed and conceived the review."/>
 <result pre="Korea (19172MFDS255). References References AdarY.SingerY.LeviR.TzehovalE.PerkS.Banet-NoachC.et al.. (2009). A universal epitope-based" exact="influenza" post="vaccine and its efficacy against H5N1. Vaccine27, 2099–2107. 10.1016/j.vaccine.2009.02.01119356612"/>
 <result pre="2099–2107. 10.1016/j.vaccine.2009.02.01119356612 AmbroseC. S.LevinM. J. (2012). The rationale for quadrivalent" exact="influenza" post="vaccines. Hum. Vaccin Immunother.8, 81–88. 10.4161/hv.8.1.1762322252006 Ana-Sosa-BatizF.VandervenH.JegaskandaS.JohnstonA.RockmanS.LaurieK.et al.. (2016)."/>
 <result pre="al.. (2017). Natural and directed antigenic drift of the H1" exact="influenza" post="virus hemagglutinin stalk domain. Sci. Rep.7:14614. 10.1038/s41598-017-14931-729097696 AntrobusR. D.LillieP."/>
 <result pre="D.LillieP. J.BerthoudT. K.SpencerA. J.McLarenJ. E.LadellK.et al.. (2012). A T cell-inducing" exact="influenza" post="vaccine for the elderly: safety and immunogenicity of MVA-NP+M1"/>
 <result pre="ONE7:e48322. 10.1371/journal.pone.004832223118984 ArevaloM. T.LiJ.Diaz-ArevaloD.ChenY.NavarroA.WuL.et al.. (2017). A dual purpose universal" exact="influenza" post="vaccine candidate confers protective immunity against anthrax. Immunology150, 276–289."/>
 <result pre="(2008). Immunomic analysis of the repertoire of T-cell specificities for" exact="influenza" post="A virus in humans. J. Virol.82, 12241–12251. 10.1128/JVI.01563-0818842709 Asthagiri"/>
 <result pre="Asthagiri ArunkumarG.IoannouA.WohlboldT. J.MeadeP.AslamS.AmanatF.et al.. (2019). Broadly cross-reactive, nonneutralizing antibodies against" exact="influenza" post="B virus hemagglutinin demonstrate effector function-dependent protection against lethal"/>
 <result pre="A.YinL.TerajimaM. (2012). A human CD4+ T cell epitope in the" exact="influenza" post="hemagglutinin is cross-reactive to influenza A virus subtypes and"/>
 <result pre="T cell epitope in the influenza hemagglutinin is cross-reactive to" exact="influenza" post="A virus subtypes and to influenza B virus. J."/>
 <result pre="hemagglutinin is cross-reactive to influenza A virus subtypes and to" exact="influenza" post="B virus. J. Virol.86, 9233–9243. 10.1128/JVI.06325-1122718815 BajicG.MaronM. J.AdachiY.OnoderaT.McCarthyK. R.McGeeC."/>
 <result pre="der PoelC. E.KuraokaM.SchmidtA. G.CarrollM. C.KelsoeG.et al.. (2019b). Autoreactivity profiles of" exact="influenza" post="hemagglutinin broadly neutralizing antibodies. Sci. Rep.9:3492. 10.1038/s41598-019-40175-830837606 BangaruS.ZhangH.GilchukI. M.VossT."/>
 <result pre="monoclonal neutralizing antibody that targets a unique conserved epitope on" exact="influenza" post="HA. Nat. Commun.9:2669. 10.1038/s41467-018-04704-929991715 BazM.BoonnakK.PaskelM.SantosC.PowellT.TownsendA.et al.. (2015). Nonreplicating influenza"/>
 <result pre="on influenza HA. Nat. Commun.9:2669. 10.1038/s41467-018-04704-929991715 BazM.BoonnakK.PaskelM.SantosC.PowellT.TownsendA.et al.. (2015). Nonreplicating" exact="influenza" post="A virus vaccines confer broad protection against lethal challenge."/>
 <result pre="(2000). Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal" exact="influenza" post="virus vaccine against a variant (A/Sydney) not contained in"/>
 <result pre="monoclonal antibody directed against a novel conserved epitope on the" exact="influenza" post="virus H3 hemagglutinin globular head. J. Virol.88, 6743–6750. 10.1128/JVI.03562-1324696468"/>
 <result pre="and recombinant hemagglutinin provide strong and broadly protective immunity against" exact="influenza" post="virus infections. Front. Immunol.9:2060. 10.3389/fimmu.2018.0206030271406 BessaJ.SchmitzN.HintonH. J.SchwarzK.JegerlehnerA.BachmannM. F. (2008)."/>
 <result pre="M.van AmerongenG.VerburghR. J.van TrierumS. E.et al.. (2011). Vaccination against seasonal" exact="influenza" post="A/H3N2 virus reduces the induction of heterosubtypic immunity against"/>
 <result pre="influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against" exact="influenza" post="A/H5N1 virus infection in ferrets. J. Virol.85, 2695–2702. 10.1128/JVI.02371-1021228239"/>
 <result pre="ferrets. J. Virol.85, 2695–2702. 10.1128/JVI.02371-1021228239 BragstadK.VinnerL.HansenM. S.NielsenJ.FomsgaardA. (2013). A polyvalent" exact="influenza" post="A DNA vaccine induces heterologous immunity and protects pigs"/>
 <result pre="2281–2288. 10.1016/j.vaccine.2013.02.06123499598 BrandenburgB.KoudstaalW.GoudsmitJ.KlarenV.TangC.BujnyM. V.et al.. (2013). Mechanisms of hemagglutinin targeted" exact="influenza" post="virus neutralization. PLoS ONE8:e80034. 10.1371/journal.pone.008003424348996 BrazzoliM.MaginiD.BonciA.BuccatoS.GiovaniC.KratzerR.et al.. (2016). Induction"/>
 <result pre="broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding" exact="influenza" post="virus hemagglutinin. J. Virol.90, 332–344. 10.1128/JVI.01786-1526468547 CarterD. M.DarbyC. A.LefoleyB."/>
 <result pre="ChaiN.SwemL. R.ParkS.NakamuraG.ChiangN.EstevezA.et al. (2017). A broadly protective therapeutic antibody against" exact="influenza" post="B virus with two mechanisms of action. Nat. Commun.8:1423410.1038/ncomms1423428102191"/>
 <result pre="Nat. Commun.8:1423410.1038/ncomms1423428102191 ChaiN.SwemL. R.ReicheltM.Chen-HarrisH.LuisE.ParkS.et al.. (2016). Two escape mechanisms of" exact="influenza" post="A virus to a broadly neutralizing stalk-binding antibody. PLoS"/>
 <result pre="ChenY. Q.LanL. Y.HuangM.HenryC.WilsonP. C. (2019). Hemagglutinin stalk-reactive antibodies interfere with" exact="influenza" post="virus neuraminidase activity by steric hindrance. J. Virol.93:e01526–18. 10.1128/JVI.01526-1830518651"/>
 <result pre="cellular immune responses elicited by the live attenuated and inactivated" exact="influenza" post="vaccines and their roles in heterologous protection in ferrets."/>
 <result pre="power of T cells: the promising hope for a universal" exact="influenza" post="vaccine. Vaccines6:18. 10.3390/vaccines602001829587436 CohenJ. (1993). Naked DNA points way"/>
 <result pre="S.MoinS. M.YassineH. M.CagigiA.KanekiyoM.Boyoglu-BarnumS.et al.. (2019). Design of nanoparticulate group 2" exact="influenza" post="virus hemagglutinin stem antigens that activate unmutated ancestor B"/>
 <result pre="plasma cells that binds to group 1 and group 2" exact="influenza" post="A hemagglutinins. Science333, 850–856. 10.1126/science.120566921798894 CouchR. B.AtmarR. L.FrancoL. M.QuarlesJ."/>
 <result pre="(2013). Antibody correlates and predictors of immunity to naturally occurring" exact="influenza" post="in humans and the importance of antibody to the"/>
 <result pre="CroweJ. E.Jr. (2018). Is it possible to develop a &quot;universal�?" exact="influenza" post="virus vaccine? potential for a universal influenza vaccine. Cold"/>
 <result pre="develop a &quot;universal�? influenza virus vaccine? potential for a universal" exact="influenza" post="vaccine. Cold Spring Harb. Perspect. Biol.10:a029496. 10.1101/cshperspect.a02949628663208 De FiletteM.FiersW.MartensW.BirkettA.RamneA.LowenadlerB.et"/>
 <result pre="(2006). Improved design and intranasal delivery of an M2e-based human" exact="influenza" post="A vaccine. Vaccine24, 6597–6601. 10.1016/j.vaccine.2006.05.08216814430 DengL.ChoK. J.FiersW.SaelensX. (2015a). M2e-based"/>
 <result pre="A vaccine. Vaccine24, 6597–6601. 10.1016/j.vaccine.2006.05.08216814430 DengL.ChoK. J.FiersW.SaelensX. (2015a). M2e-based universal" exact="influenza" post="a vaccines. Vaccines3, 105–136. 10.3390/vaccines301010526344949 DengL.IbanezL. I.Van den BosscheV.RooseK.YoussefS."/>
 <result pre="DengL.IbanezL. I.Van den BosscheV.RooseK.YoussefS. A.de BruinA.et al.. (2015b). Protection against" exact="influenza" post="A virus challenge with M2e-displaying filamentous Escherichia coli phages."/>
 <result pre="al.. (2018). Double-layered protein nanoparticles induce broad protection against divergent" exact="influenza" post="A viruses. Nat. Commun.9:359. 10.1038/s41467-017-02725-429367723 DenisJ.Acosta-RamirezE.ZhaoY.HamelinM. E.KoukavicaI.BazM.et al.. (2008)."/>
 <result pre="Commun.9:359. 10.1038/s41467-017-02725-429367723 DenisJ.Acosta-RamirezE.ZhaoY.HamelinM. E.KoukavicaI.BazM.et al.. (2008). Development of a universal" exact="influenza" post="A vaccine based on the M2e peptide fused to"/>
 <result pre="10.1016/j.vaccine.2008.04.05218511159 DeZureA. D.CoatesE. E.HuZ.YamshchikovG. V.ZephirK. L.EnamaM. E.et al.. (2017). An" exact="avian influenza" post="H7 DNA priming vaccine is safe and immunogenic in"/>
 <result pre="DeZureA. D.CoatesE. E.HuZ.YamshchikovG. V.ZephirK. L.EnamaM. E.et al.. (2017). An avian" exact="influenza" post="H7 DNA priming vaccine is safe and immunogenic in"/>
 <result pre="neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against" exact="influenza" post="virus in vivo. Nat. Med.20, 143–151. 10.1038/nm.344324412922 DoyleT. M.HashemA."/>
 <result pre="M.HashemA. M.LiC.Van DomselaarG.LarocqueL.WangJ.et al.. (2013a). Universal anti-neuraminidase antibody inhibiting all" exact="influenza" post="A subtypes. Antiviral Res.100, 567–574. 10.1016/j.antiviral.2013.09.01824091204 DoyleT. M.LiC.BucherD. J.HashemA."/>
 <result pre="(2013b). A monoclonal antibody targeting a highly conserved epitope in" exact="influenza" post="B neuraminidase provides protection against drug resistant strains. Biochem."/>
 <result pre="DreyfusC.LaursenN. S.KwaksT.ZuijdgeestD.KhayatR.EkiertD. C.et al.. (2012). Highly conserved protective epitopes on" exact="influenza" post="B viruses. Science337, 1343–1348. 10.1126/science.122290822878502 DuanS.ThomasP. G. (2016). Balancing"/>
 <result pre="immune protection and immune pathology by CD8(+) T-cell responses to" exact="influenza" post="infection. Front. Immunol.7:25. 10.3389/fimmu.2016.0002526904022 DucatezM. F.BahlJ.GriffinY.Stigger-RosserE.FranksJ.BarmanS.et al.. (2011). Feasibility"/>
 <result pre="10.3389/fimmu.2016.0002526904022 DucatezM. F.BahlJ.GriffinY.Stigger-RosserE.FranksJ.BarmanS.et al.. (2011). Feasibility of reconstructed ancestral H5N1" exact="influenza" post="viruses for cross-clade protective vaccine development. Proc. Natl. Acad."/>
 <result pre="F.WebbA.CrumptonJ. C.WebbyR. J. (2013). Long-term vaccine-induced heterologous protection against H5N1" exact="influenza" post="viruses in the ferret model. Influenza Other Respir. Viruses7,"/>
 <result pre="E. (1980). A clinical, epidemiologic, serologic, and virologic study of" exact="influenza" post="C virus infection. Arch. Intern. Med.140, 1295–1298. 10.1001/archinte.1980.003302100430217425764 EasterbrookJ."/>
 <result pre="M.GaoJ.KashJ. C.MorensD. M.CouzensL.et al.. (2012). Protection against a lethal H5N1" exact="influenza" post="challenge by intranasal immunization with virus-like particles containing 2009"/>
 <result pre="39–44. 10.1016/j.virol.2012.06.00322727831 EgginkD.GoffP. H.PaleseP. (2014). Guiding the immune response against" exact="influenza" post="virus hemagglutinin toward the conserved stalk domain by hyperglycosylation"/>
 <result pre="S. (2019). Neuraminidase, the forgotten surface antigen, emerges as an" exact="influenza" post="vaccine target for broadened protection. J. Infect. Dis.219(Suppl 1),"/>
 <result pre="A.FriesenR. H.JongeneelenM.ThrosbyM.et al.. (2009). Antibody recognition of a highly conserved" exact="influenza" post="virus epitope. Science324, 246–251. 10.1126/science.117149119251591 EkiertD. C.FriesenR. H.BhabhaG.KwaksT.JongeneelenM.YuW.et al.."/>
 <result pre="al.. (2011). A highly conserved neutralizing epitope on group 2" exact="influenza" post="A viruses. Science333, 843–850. 10.1126/science.120483921737702 EkiertD. C.KashyapA. K.SteelJ.RubrumA.BhabhaG.KhayatR.et al.."/>
 <result pre="Science333, 843–850. 10.1126/science.120483921737702 EkiertD. C.KashyapA. K.SteelJ.RubrumA.BhabhaG.KhayatR.et al.. (2012). Cross-neutralization of" exact="influenza" post="A viruses mediated by a single antibody loop. Nature489,"/>
 <result pre="G.El BakkouriK.SchonK.RamneA.FestjensE.LowenadlerB.et al.. (2008). CTA1-M2e-DD: a novel mucosal adjuvant targeted" exact="influenza" post="vaccine. Vaccine26, 1243–1252. 10.1016/j.vaccine.2007.12.02718243429 EliassonD. G.OmokanyeA.SchonK.WenzelU. A.BernasconiV.BemarkM.et al.. (2018)."/>
 <result pre="(2018). M2e-tetramer-specific memory CD4 T cells are broadly protective against" exact="influenza" post="infection. Mucosal Immunol.11, 273–289. 10.1038/mi.2017.1428295019 ErbeldingE. J.PostD. J.StemmyE. J.RobertsP."/>
 <result pre="ErbeldingE. J.PostD. J.StemmyE. J.RobertsP. C.AugustineA. D.FergusonS.et al.. (2018). A universal" exact="influenza" post="vaccine: the strategic plan for the National Institute of"/>
 <result pre="E.KirkpatrickE.SunW.HaiR.AmanatF.ChromikovaV.et al.. (2017). Chimeric hemagglutinin constructs induce broad protection against" exact="influenza" post="B virus challenge in the mouse model. J. Virol.91:e00286–17."/>
 <result pre="J. Virol.91:e00286–17. 10.1128/JVI.00286-1728356526 EstradaL. D.Schultz-CherryS. (2019). Development of a universal" exact="influenza" post="vaccine. J. Immunol. 202, 392–398. 10.4049/jimmunol.180105430617121 FolegattiP. M.BellamyD.FlaxmanA.MairC.EllisC.RamonR. L.et"/>
 <result pre="M.BellamyD.FlaxmanA.MairC.EllisC.RamonR. L.et al.. (2019). Safety and immunogenicity of the heterosubtypic" exact="influenza" post="A vaccine MVA-NP+M1 mnufactured on the AGE1.CR.pIX avian cell"/>
 <result pre="(2008). Correlation of cellular immune responses with protection against culture-confirmed" exact="influenza" post="virus in young children. Clin. Vaccine Immunol.15, 1042–1053. 10.1128/CVI.00397-0718448618"/>
 <result pre="M.EkiertD. C.BhabhaG.et al.. (2014). A common solution to group 2" exact="influenza" post="virus neutralization. Proc. Natl. Acad. Sci. U.S.A.111, 445–450. 10.1073/pnas.131905811024335589"/>
 <result pre="Natl. Acad. Sci. U.S.A.111, 445–450. 10.1073/pnas.131905811024335589 GaoX.WangW.LiY.ZhangS.DuanY.XingL.et al.. (2013). Enhanced" exact="influenza" post="VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects"/>
 <result pre="GaugerP. C.VincentA. L.LovingC. L.LagerK. M.JankeB. H.KehrliM. E.Jr.et al.. (2011). Enhanced" exact="pneumonia" post="and disease in pigs vaccinated with an inactivated human-like"/>
 <result pre="human-like (delta-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1" exact="influenza" post="virus. Vaccine29, 2712–2719. 10.1016/j.vaccine.2011.01.08221310191 GianfraniC.OseroffC.SidneyJ.ChesnutR. W.SetteA. (2000). Human memory"/>
 <result pre="10.1016/j.vaccine.2011.01.08221310191 GianfraniC.OseroffC.SidneyJ.ChesnutR. W.SetteA. (2000). Human memory CTL response specific for" exact="influenza" post="A virus is broad and multispecific. Hum. Immunol.61, 438–452."/>
 <result pre="GosticK. M.AmbroseM.WorobeyM.Lloyd-SmithJ. O. (2016). Potent protection against H5N1 and H7N9" exact="influenza" post="via childhood hemagglutinin imprinting. Science354, 722–726. 10.1126/science.aag132227846599 GrasS.KedzierskiL.ValkenburgS. A.LaurieK.LiuY."/>
 <result pre="Cross-reactive CD8 T-cell immunity between the pandemic H1N1–2009 and H1N1–1918" exact="influenza" post="A viruses. Proc. Natl. Acad. Sci. U.S.A.107, 12599–12604. 10.1073/pnas.100727010720616031"/>
 <result pre="U.S.A.107, 12599–12604. 10.1073/pnas.100727010720616031 GravesP. N.SchulmanJ. L.YoungJ. F.PaleseP. (1983). Preparation of" exact="influenza" post="virus subviral particles lacking the HA1 subunit of hemagglutinin:"/>
 <result pre="conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against" exact="influenza" post="virus infection. Microbes Infect.19, 641–647. 10.1016/j.micinf.2017.08.01028903071 HaY.StevensD. J.SkehelJ. J.WileyD."/>
 <result pre="HaY.StevensD. J.SkehelJ. J.WileyD. C. (2002). H5 avian and H9 swine" exact="influenza" post="virus haemagglutinin structures: possible origin of influenza subtypes. EMBO"/>
 <result pre="and H9 swine influenza virus haemagglutinin structures: possible origin of" exact="influenza" post="subtypes. EMBO J.21, 865–875. 10.1093/emboj/21.5.86511867515 HaiR.KrammerF.TanG. S.PicaN.EgginkD.MaamaryJ.et al.. (2012)."/>
 <result pre="J. Virol.86, 5774–5781. 10.1128/JVI.00137-1222398287 HannounC. (2013). The evolving history of" exact="influenza" post="viruses and influenza vaccines. Exp. Rev. Vaccines12, 1085–1094. 10.1586/14760584.2013.82470924024871"/>
 <result pre="10.1128/JVI.00137-1222398287 HannounC. (2013). The evolving history of influenza viruses and" exact="influenza" post="vaccines. Exp. Rev. Vaccines12, 1085–1094. 10.1586/14760584.2013.82470924024871 HashemiH.PouyanfardS.BandehpourM.NoroozbabaeiZ.KazemiB.SaelensX.et al.. (2012)."/>
 <result pre="al.. (2012). Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against" exact="influenza" post="A virus challenge. PLoS ONE7:e45765. 10.1371/journal.pone.004576523029232 HashimotoY.MokiT.TakizawaT.ShiratsuchiA.NakanishiY. (2007). Evidence"/>
 <result pre="challenge. PLoS ONE7:e45765. 10.1371/journal.pone.004576523029232 HashimotoY.MokiT.TakizawaT.ShiratsuchiA.NakanishiY. (2007). Evidence for phagocytosis of" exact="influenza" post="virus-infected, apoptotic cells by neutrophils and macrophages in mice."/>
 <result pre="J. Immunol.178, 2448–2457. 10.4049/jimmunol.178.4.244817277152 HattaY.BoltzD.SarawarS.KawaokaY.NeumannG.BilselP. (2017). M2SR, a novel live" exact="influenza" post="vaccine, protects mice and ferrets against highly pathogenic avian"/>
 <result pre="live influenza vaccine, protects mice and ferrets against highly pathogenic" exact="avian influenza." post="Vaccine35, 4177–4183. 10.1016/j.vaccine.2017.06.03928668565 HattaY.BoltzD.SarawarS.KawaokaY.NeumannG.BilselP. (2018). Novel influenza vaccine M2SR"/>
 <result pre="highly pathogenic avian influenza. Vaccine35, 4177–4183. 10.1016/j.vaccine.2017.06.03928668565 HattaY.BoltzD.SarawarS.KawaokaY.NeumannG.BilselP. (2018). Novel" exact="influenza" post="vaccine M2SR protects against drifted H1N1 and H3N2 influenza"/>
 <result pre="Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2" exact="influenza" post="virus challenge in ferrets with pre-existing immunity. Vaccine36, 5097–5103."/>
 <result pre="responses in children and adults receiving inactivated or live attenuated" exact="influenza" post="vaccines. J. Virol.80, 11756–11766. 10.1128/JVI.01460-0616971435 HemannE. A.KangS. M.LeggeK. L."/>
 <result pre="A.KangS. M.LeggeK. L. (2013). Protective CD8 T cell-mediated immunity against" exact="influenza" post="A virus infection following influenza virus-like particle vaccination. J."/>
 <result pre="CD8 T cell-mediated immunity against influenza A virus infection following" exact="influenza" post="virus-like particle vaccination. J. Immunol.191, 2486–2494. 10.4049/jimmunol.130095423885108 Henry DunandC."/>
 <result pre="Y.AndrewsS.et al.. (2015). Preexisting human antibodies neutralize recently emerged H7N9" exact="influenza" post="strains. J. Clin. Invest.125, 1255–1268. 10.1172/JCI7437425689254 HenryC.PalmA. E.KrammerF.WilsonP. C."/>
 <result pre="E.KrammerF.WilsonP. C. (2018). From original antigenic sin to the universal" exact="influenza" post="virus vaccine. Trends Immunol.39, 70–79. 10.1016/j.it.2017.08.00328867526 HesselA.Savidis-DachoH.CoulibalyS.PortsmouthD.KreilT. R.CroweB. A.et"/>
 <result pre="10.1016/j.it.2017.08.00328867526 HesselA.Savidis-DachoH.CoulibalyS.PortsmouthD.KreilT. R.CroweB. A.et al.. (2014). MVA vectors expressing conserved" exact="influenza" post="proteins protect mice against lethal challenge with H5N1, H9N2"/>
 <result pre="TrierumS. E.KreijtzJ. H.BodewesR.Geelhoed-MierasM. M.NieuwkoopN. J.et al.. (2011). Cross-protective immunity against" exact="influenza" post="pH1N1 2009 viruses induced by seasonal influenza A (H3N2)"/>
 <result pre="Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal" exact="influenza" post="A (H3N2) virus is mediated by virus-specific T-cells. J."/>
 <result pre="HiranoD.OhshimaN.Kubota-KoketsuR.YamasakiA.KurosawaG.OkunoY.et al.. (2018). Three types of broadly reacting antibodies against" exact="influenza" post="B viruses induced by vaccination with seasonal influenza viruses."/>
 <result pre="antibodies against influenza B viruses induced by vaccination with seasonal" exact="influenza" post="viruses. J. Immunol. Res.2018:7251793. 10.1155/2018/725179329854845 HoftD. F.BabusisE.WorkuS.SpencerC. T.LottenbachK.TruscottS. M.et"/>
 <result pre="10.1155/2018/725179329854845 HoftD. F.BabusisE.WorkuS.SpencerC. T.LottenbachK.TruscottS. M.et al.. (2011). Live and inactivated" exact="influenza" post="vaccines induce similar humoral responses, but only live vaccines"/>
 <result pre="Fc receptor-mediated phagocytosis makes a significant contribution to clearance of" exact="influenza" post="virus infections. J. Immunol.166, 7381–7388. 10.4049/jimmunol.166.12.738111390489 IbaY.FujiiY.OhshimaN.SumidaT.Kubota-KoketsuR.IkedaM.et al.. (2014)."/>
 <result pre="Conserved neutralizing epitope at globular head of hemagglutinin in H3N2" exact="influenza" post="viruses. J. Virol. 88, 7130–7144. 10.1128/JVI.00420-1424719430 IbanezL. I.RooseK.De FiletteM.SchotsaertM.De"/>
 <result pre="associated RNA promote T helper 1 type adaptive immunity against" exact="influenza" post="A. PLoS ONE8:e59081. 10.1371/journal.pone.005908123527091 ImpagliazzoA.MilderF.KuipersH.WagnerM. V.ZhuX.HoffmanR. M.et al.. (2015)."/>
 <result pre="ONE8:e59081. 10.1371/journal.pone.005908123527091 ImpagliazzoA.MilderF.KuipersH.WagnerM. V.ZhuX.HoffmanR. M.et al.. (2015). A stable trimeric" exact="influenza" post="hemagglutinin stem as a broadly protective immunogen. Science349, 1301–1306."/>
 <result pre="(2018). Broadly protective anti-hemagglutinin stalk antibodies induced by live attenuated" exact="influenza" post="vaccine expressing chimeric hemagglutinin. Virology518, 313–323. 10.1016/j.virol.2018.03.01329574336 JamesonJ.CruzJ.EnnisF. A."/>
 <result pre="313–323. 10.1016/j.virol.2018.03.01329574336 JamesonJ.CruzJ.EnnisF. A. (1998). Human cytotoxic T-lymphocyte repertoire to" exact="influenza" post="A viruses. J. Virol.72, 8682–8689. 9765409 JangY. H.ByunY. H.LeeD."/>
 <result pre="H.et al.. (2013a). Cold-adapted X-31 live attenuated 2009 pandemic H1N1" exact="influenza" post="vaccine elicits protective immune responses in mice and ferrets."/>
 <result pre="H.LeeY. J.LeeY. H.LeeK. H.SeongB. L. (2012). Cold-adapted pandemic 2009 H1N1" exact="influenza" post="virus live vaccine elicits cross-reactive immune responses against seasonal"/>
 <result pre="live vaccine elicits cross-reactive immune responses against seasonal and H5" exact="influenza" post="A viruses. J. Virol.86, 5953–5958. 10.1128/JVI.07149-1122438541 JangY. H.JungE. J.ByunY."/>
 <result pre="and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1" exact="influenza" post="vaccines. Vaccine31, 3339–3346. 10.1016/j.vaccine.2013.05.08023742997 JangY. H.JungE. J.LeeK. H.ByunY. H.YangS."/>
 <result pre="L. (2016). Genetic analysis of attenuation markers of cold-adapted X-31" exact="influenza" post="live vaccine donor strain. Vaccine34, 1343–1349. 10.1016/j.vaccine.2016.01.05326851733 JangY. H.KimJ."/>
 <result pre="(2018). Pan-influenza A protection by prime-boost vaccination with cold-adapted live-attenuated" exact="influenza" post="vaccine in a mouse model. Front. Immunol.9:116. 10.3389/fimmu.2018.0011629449842 JangY."/>
 <result pre="Protective efficacy in mice of monovalent and trivalent live attenuated" exact="influenza" post="vaccines in the background of cold-adapted A/X-31 and B/Lee/40"/>
 <result pre="H.SeongB. L. (2013a). Cross-protective immune responses elicited by live attenuated" exact="influenza" post="vaccines. Yonsei Med. J. 54, 271–282. 10.3349/ymj.2013.54.2.27123364956 JangY. H.SeongB."/>
 <result pre="54, 271–282. 10.3349/ymj.2013.54.2.27123364956 JangY. H.SeongB. L. (2013b). Toward a universal" exact="influenza" post="vaccine: from the perspective of protective efficacy. Clin. Exp."/>
 <result pre="H.SeongB. L. (2014). Options and obstacles for designing a universal" exact="influenza" post="vaccine. Viruses6, 3159–3180. 10.3390/v608315925196381 JanjuaN. Z.SkowronskiD. M.HottesT. S.OseiW.AdamsE.PetricM.et al.."/>
 <result pre="Viruses6, 3159–3180. 10.3390/v608315925196381 JanjuaN. Z.SkowronskiD. M.HottesT. S.OseiW.AdamsE.PetricM.et al.. (2010). Seasonal" exact="influenza" post="vaccine and increased risk of pandemic A/H1N1-related illness: first"/>
 <result pre="1017–1027. 10.1086/65658620887210 JeffersonT.Di PietrantonjC.RivettiA.BawazeerG. A.Al-AnsaryL. A.FerroniE. (2010). Vaccines for preventing" exact="influenza" post="in healthy adults. Cochrane Database Syst. Rev.7:Cd00126910.1002/14651858.CD001269.pub4 JeffersonT.RivettiA.HarndenA.Di PietrantonjC.DemicheliV."/>
 <result pre="Cochrane Database Syst. Rev.7:Cd00126910.1002/14651858.CD001269.pub4 JeffersonT.RivettiA.HarndenA.Di PietrantonjC.DemicheliV. (2008). Vaccines for preventing" exact="influenza" post="in healthy children. Cochrane Database Syst. Rev.16:Cd00487910.1002/14651858.CD004879.pub3 JegaskandaS.CoM. D."/>
 <result pre="Induction of H7N9-cross-reactive antibody-dependent cellular cytotoxicity antibodies by human seasonal" exact="influenza" post="A viruses that are directed toward the nucleoprotein. J."/>
 <result pre="cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging" exact="influenza" post="viruses. J. Infect. Dis.210, 1811–1822. 10.1093/infdis/jiu33424916185 JegaskandaS.VandervenH. A.WheatleyA. K.KentS."/>
 <result pre="is the question: antibody Fc-receptor interactions are key to universal" exact="influenza" post="vaccine design. Hum. Vaccin Immunother.13, 1–9. 10.1080/21645515.2017.129001828332900 JegerlehnerA.SchmitzN.StorniT.BachmannM. F."/>
 <result pre="5598–5605. 10.4049/jimmunol.172.9.559815100303 JobE. R.YsenbaertT.SmetA.ChristopoulouI.StrugnellT.OlooE. O.et al.. (2018). Broadened immunity against" exact="influenza" post="by vaccination with computationally designed influenza virus N1 neuraminidase"/>
 <result pre="(2018). Broadened immunity against influenza by vaccination with computationally designed" exact="influenza" post="virus N1 neuraminidase constructs. NPJ Vaccines3:55. 10.1038/s41541-018-0093-130510776 JohanssonB. E.KilbourneE."/>
 <result pre="constructs. NPJ Vaccines3:55. 10.1038/s41541-018-0093-130510776 JohanssonB. E.KilbourneE. D. (1993). Dissociation of" exact="influenza" post="virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition."/>
 <result pre="D. (1996). Immunization with dissociated neuraminidase, matrix, and nucleoproteins from" exact="influenza" post="A virus eliminates cognate help and antigenic competition. Virology225,"/>
 <result pre="and helper T cells cooperatively mediate intravirionic antigenic competition between" exact="influenza" post="A virus surface glycoproteins. Proc. Natl. Acad. Sci. U.S.A.84,"/>
 <result pre="(2019). Induction of protective immune response to intranasal administration of" exact="influenza" post="virus-like particles in a mouse model. J. Cell Physiol."/>
 <result pre="226, 1110–1117. 10.1002/jcp.28339 KhuranaS. (2018). Development and regulation of novel" exact="influenza" post="virus vaccines: a United States young scientist perspective. Vaccines6:24."/>
 <result pre="al.. (2013). Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance" exact="influenza" post="virus respiratory disease. Sci. Transl. Med.5:200ra114. 10.1126/scitranslmed.300636623986398 KilbourneE. D."/>
 <result pre="Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus" exact="respiratory disease." post="Sci. Transl. Med.5:200ra114. 10.1126/scitranslmed.300636623986398 KilbourneE. D. (2006). Influenza pandemics"/>
 <result pre="Neuraminidase expressing virus-like particle vaccine provides effective cross protection against" exact="influenza" post="virus. Virology535, 179–188. 10.1016/j.virol.2019.07.00831310875 KimM. C.LeeJ. W.ChoiH. J.LeeY. N.HwangH."/>
 <result pre="skin of virus-like particles containing heterologous M2e extracellular domains of" exact="influenza" post="virus induces broad heterosubtypic cross-protection. J. Control Release210, 208–216."/>
 <result pre="key role in inducing humoral and cellular immune responses to" exact="influenza" post="virus strain-specific hemagglutinin-based or cross-protective M2 extracellular domain-based vaccination."/>
 <result pre="T.KimM. C.LeeY. N.KimK. H.KoE. J.et al.. (2017). Cross-protective efficacy of" exact="influenza" post="virus M2e containing virus-like particles is superior to hemagglutinin"/>
 <result pre="backgrounds of mice. Front. Immunol.8:1730. 10.3389/fimmu.2017.0173029276514 KirkpatrickE.QiuX.WilsonP. C.BahlJ.KrammerF. (2018). The" exact="influenza" post="virus hemagglutinin head evolves faster than the stalk domain."/>
 <result pre="DNA vaccine induces protective cross-reactive T cell responses against heterologous" exact="influenza" post="virus in nonhuman primates. PLoS ONE12:e0189780. 10.1371/journal.pone.018978029267331 KosikI.AngelettiD.GibbsJ. S.AngelM.TakedaK.KosikovaM.et"/>
 <result pre="ONE12:e0189780. 10.1371/journal.pone.018978029267331 KosikI.AngelettiD.GibbsJ. S.AngelM.TakedaK.KosikovaM.et al.. (2019). Neuraminidase inhibition contributes to" exact="influenza" post="A virus neutralization by anti-hemagglutinin stem antibodies. J. Exp."/>
 <result pre="A.CrawfordJ. C.RizzettoS.et al.. (2019). Human CD8(+) T cell cross-reactivity across" exact="influenza" post="A, B and C viruses. Nat. Immunol.20, 613–625. 10.1038/s41590-019-0320-630778243"/>
 <result pre="Immunol.20, 613–625. 10.1038/s41590-019-0320-630778243 KrammerF. (2019). The human antibody response to" exact="influenza" post="A virus infection and vaccination. Nat. Rev. Immunol.19, 383–397."/>
 <result pre="al.. (2018a). NAction! How can neuraminidase-based immunity contribute to better" exact="influenza" post="virus vaccines?MBio9:e02332–e02317. 10.1128/mBio.02332-1729615508 KrammerF.Garcia-SastreA.PaleseP. (2018b). Is it possible to"/>
 <result pre="10.1128/mBio.02332-1729615508 KrammerF.Garcia-SastreA.PaleseP. (2018b). Is it possible to develop a &quot;universal�?" exact="influenza" post="virus vaccine? Potential target antigens and critical aspects for"/>
 <result pre="vaccine? Potential target antigens and critical aspects for a universal" exact="influenza" post="vaccine. Cold Spring Harb Perspect. Biol.10:a028845. 10.1101/cshperspect.a02884528663209 KrammerF.HaiR.YondolaM.TanG. S.Leyva-GradoV."/>
 <result pre="Biol.10:a028845. 10.1101/cshperspect.a02884528663209 KrammerF.HaiR.YondolaM.TanG. S.Leyva-GradoV. H.RyderA. B.et al.. (2014). Assessment of" exact="influenza" post="virus hemagglutinin stalk-based immunity in ferrets. J. Virol.88, 3432–3442."/>
 <result pre="Virol.3, 521–530. 10.1016/j.coviro.2013.07.00723978327 KrammerF.PaleseP. (2015). Advances in the development of" exact="influenza" post="virus vaccines. Nat. Rev. Drug Discov.14, 167–182. 10.1038/nrd452925722244 KrammerF.PicaN.HaiR.MargineI.PaleseP."/>
 <result pre="Nat. Rev. Drug Discov.14, 167–182. 10.1038/nrd452925722244 KrammerF.PicaN.HaiR.MargineI.PaleseP. (2013). Chimeric hemagglutinin" exact="influenza" post="virus vaccine constructs elicit broadly protective stalk-specific antibodies. J."/>
 <result pre="monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2" exact="influenza" post="viruses. J. Virol.86, 6334–6340. 10.1128/JVI.07158-1122457520 KrauseJ. C.TsibaneT.TumpeyT. M.HuffmanC. J.BaslerC."/>
 <result pre="a conserved, novel epitope on the globular head of the" exact="influenza" post="H1N1 virus hemagglutinin. J. Virol.85, 10905–10908. 10.1128/JVI.00700-1121849447 KreijtzJ. H.BodewesR.van"/>
 <result pre="10905–10908. 10.1128/JVI.00700-1121849447 KreijtzJ. H.BodewesR.van AmerongenG.KuikenT.FouchierR. A.OsterhausA. D.et al.. (2007). Primary" exact="influenza" post="A virus infection induces cross-protective immunity against a lethal"/>
 <result pre="MutsertG.BaasC.van AmerongenG.et al.. (2009). Infection of mice with a human" exact="influenza" post="A/H3N2 virus induces protective immunity against lethal infection with"/>
 <result pre="influenza A/H3N2 virus induces protective immunity against lethal infection with" exact="influenza" post="A/H5N1 virus. Vaccine27, 4983–4989. 10.1016/j.vaccine.2009.05.07919538996 KreijtzJ. H.de MutsertG.van BaalenC."/>
 <result pre="BaalenC. A.FouchierR. A.OsterhausA. D.RimmelzwaanG. F. (2008). Cross-recognition of avian H5N1" exact="influenza" post="virus by human cytotoxic T-lymphocyte populations directed to human"/>
 <result pre="influenza virus by human cytotoxic T-lymphocyte populations directed to human" exact="influenza" post="A virus. J. Virol.82, 5161–5166. 10.1128/JVI.02694-0718353950 LeclercD.RivestM.BabinC.Lopez-MaciasC.SavardP. (2013). A"/>
 <result pre="identify the minimum interval necessary to observe the H5 DNA" exact="influenza" post="vaccine priming effect. J. Infect. Dis.208, 418–422. 10.1093/infdis/jit18023633407 LeeJ.BoutzD."/>
 <result pre="serum antibody repertoire in young adults before and after seasonal" exact="influenza" post="vaccination. Nat. Med.22, 1456–1464. 10.1038/nm.422427820605 LeeK. H.SeongB. L. (1998)."/>
 <result pre="The position 4 nucleotide at the 3' end of the" exact="influenza" post="virus neuraminidase vRNA is involved in temporal regulation of"/>
 <result pre="and replication of neuraminidase RNAs and affects the repertoire of" exact="influenza" post="virus surface antigens. J. Gen Virol.79 (Pt 8), 1923–1934."/>
 <result pre="V.SchumacherR.et al.. (2008). Memory T cells established by seasonal human" exact="influenza" post="A infection cross-react with avian influenza A (H5N1) in"/>
 <result pre="cells established by seasonal human influenza A infection cross-react with" exact="avian influenza" post="A (H5N1) in healthy individuals. J. Clin. Invest.118, 3478–3490."/>
 <result pre="established by seasonal human influenza A infection cross-react with avian" exact="influenza" post="A (H5N1) in healthy individuals. J. Clin. Invest.118, 3478–3490."/>
 <result pre="N.KimM. C.LeeY. T.KimY. J.KangS. M. (2015). Mechanisms of cross-protection by" exact="influenza" post="virus M2-based vaccines. Immune Netw.15, 213–221. 10.4110/in.2015.15.5.21326557805 LeeY. N.LeeY."/>
 <result pre="antibodies but plays a critical role in conferring protection after" exact="influenza" post="M2 vaccination. Immunology143, 300–309. 10.1111/imm.1231024773389 LinS. C.LinY. F.ChongP.WuS. C."/>
 <result pre="and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1" exact="avian influenza" post="viruses. PLoS ONE9:e92822. 10.1371/journal.pone.009282224671139 LinY. P.GregoryV.CollinsP.KloessJ.WhartonS.CattleN.et al.. (2010). Neuraminidase"/>
 <result pre="recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian" exact="influenza" post="viruses. PLoS ONE9:e92822. 10.1371/journal.pone.009282224671139 LinY. P.GregoryV.CollinsP.KloessJ.WhartonS.CattleN.et al.. (2010). Neuraminidase"/>
 <result pre="LinY. P.GregoryV.CollinsP.KloessJ.WhartonS.CattleN.et al.. (2010). Neuraminidase receptor binding variants of human" exact="influenza" post="A(H3N2) viruses resulting from substitution of aspartic acid 151"/>
 <result pre="immunization with live-attenuated chimeric hemagglutinin-based vaccines confers heterosubtypic immunity against" exact="influenza" post="A viruses in a preclinical ferret model. Front. Immunol.10:756."/>
 <result pre="immunization with recombinant neuraminidase proteins of H5N1 and pandemic H1N1" exact="influenza" post="A viruses. J. Virol.89, 7224–7234. 10.1128/JVI.00585-1525948745 LiuY.TanH. X.KoutsakosM.JegaskandaS.EsterbauerR.TilmanisD.et al.."/>
 <result pre="X.KoutsakosM.JegaskandaS.EsterbauerR.TilmanisD.et al.. (2019b). Cross-lineage protection by human antibodies binding the" exact="influenza" post="B hemagglutinin. Nat. Commun.10:324. 10.1038/s41467-018-08165-y30659197 LowenA. C. (2017). Constraints,"/>
 <result pre="Commun.10:324. 10.1038/s41467-018-08165-y30659197 LowenA. C. (2017). Constraints, drivers, and implications of" exact="influenza" post="A virus reassortment. Annu. Rev. Virol.4, 105–121. 10.1146/annurev-virology-101416-04172628548881 LuY.WelshJ."/>
 <result pre="LuY.WelshJ. P.SwartzJ. R. (2014). Production and stabilization of the trimeric" exact="influenza" post="hemagglutinin stem domain for potentially broadly protective influenza vaccines."/>
 <result pre="the trimeric influenza hemagglutinin stem domain for potentially broadly protective" exact="influenza" post="vaccines. Proc. Natl. Acad. Sci. U.S.A.111, 125–130. 10.1073/pnas.130870111024344259 MallajosyulaV."/>
 <result pre="(2013). Hemagglutinin stalk-based universal vaccine constructs protect against group 2" exact="influenza" post="A viruses. J. Virol.87, 10435–10446. 10.1128/JVI.01715-1323903831 McMahonM.KirkpatrickE.StadlbauerD.StrohmeierS.BouvierN. M.KrammerF. (2019)."/>
 <result pre="10435–10446. 10.1128/JVI.01715-1323903831 McMahonM.KirkpatrickE.StadlbauerD.StrohmeierS.BouvierN. M.KrammerF. (2019). Mucosal immunity against neuraminidase prevents" exact="influenza" post="B virus transmission in Guinea Pigs. MBio10:e00560–19. 10.1128/mBio.00560-1931113896 MemoliM."/>
 <result pre="antihemagglutinin and antineuraminidase antibodies as correlates of protection in an" exact="influenza" post="A/H1N1 virus healthy human challenge model. MBio7:e00417–e00416. 10.1128/mBio.00417-1627094330 MesedaC."/>
 <result pre="10.1128/mBio.00417-1627094330 MesedaC. A.AtukoraleV.SotoJ.EichelbergerM. C.GaoJ.WangW.et al. (2018). Immunogenicity and protection against" exact="influenza" post="H7N3 in mice by modified vaccinia virus Ankara vectors"/>
 <result pre="Immunogenicity and protection against influenza H7N3 in mice by modified" exact="vaccinia virus" post="Ankara vectors expressing influenza virus hemagglutinin or neuraminidase. Sci."/>
 <result pre="H7N3 in mice by modified vaccinia virus Ankara vectors expressing" exact="influenza" post="virus hemagglutinin or neuraminidase. Sci. Rep.8:536410.1038/s41598-018-23712-929599502 MoglingR.RichardM. J.VlietS. V.BeekR."/>
 <result pre="J. A.SpronkenM. I.et al.. (2017). Neuraminidase-mediated haemagglutination of recent human" exact="influenza" post="A(H3N2) viruses is determined by arginine 150 flanking the"/>
 <result pre="(2015). Longevity of B-cell and T-cell responses after live attenuated" exact="influenza" post="vaccination in children. J. Infect. Dis.211, 1541–1549. 10.1093/infdis/jiu65425425696 MohnK."/>
 <result pre="10.1093/infdis/jiu65425425696 MohnK. G.SmithI.SjursenH.CoxR. J. (2018). Immune responses after live attenuated" exact="influenza" post="vaccination. Hum. Vaccin Immunother.14, 571–578. 10.1080/21645515.2017.137737628933664 MohnK. G. I.ZhouF.BrokstadK."/>
 <result pre="cross-reactive and protection-associated T cells in children after live attenuated" exact="influenza" post="vaccination. J. Infect. Dis.215, 1527–1535. 10.1093/infdis/jix16528368530 MonsalvoA. C.BatalleJ. P.LopezM."/>
 <result pre="P.LopezM. F.KrauseJ. C.KlemencJ.HernandezJ. Z.et al.. (2011). Severe pandemic 2009 H1N1" exact="influenza" post="disease due to pathogenic immune complexes. Nat. Med. 17,"/>
 <result pre="623–625. 10.1016/S0140-6736(73)92196-X4121842 MontoA. S.PetrieJ. G.CrossR. T.JohnsonE.LiuM.ZhongW.et al.. (2015). Antibody to" exact="influenza" post="virus neuraminidase: an independent correlate of protection. J. Infect."/>
 <result pre="J. Infect. Dis.212, 1191–1199. 10.1093/infdis/jiv19525858957 MozdzanowskaK.FengJ.EidM.KragolG.CudicM.OtvosL.Jr.et al.. (2003). Induction of" exact="influenza" post="type A virus-specific resistance by immunization of mice with"/>
 <result pre="M. (1972). Association of serum anti-neuraminidase antibody with resistance to" exact="influenza" post="in man. N. Engl. J. Med.286, 1329–1332. 10.1056/NEJM1972062228625025027388 MusicN.ReberA."/>
 <result pre="live-attenuated prime, inactivated boost vaccination strategy with chimeric hemagglutinin-based universal" exact="influenza" post="virus vaccines provides protection in ferrets: a confirmatory study."/>
 <result pre="study. Vaccines6:47. 10.3390/vaccines603004730044403 NachbagauerR.LiuW. C.ChoiA.WohlboldT. J.AtlasT.RajendranM.et al.. (2017). A universal" exact="influenza" post="virus vaccine candidate confers protection against pandemic H1N1 infection"/>
 <result pre="ferret studies. NPJ Vaccines2:26. 10.1038/s41541-017-0026-429263881 NeirynckS.DerooT.SaelensX.VanlandschootP.JouW. M.FiersW. (1999). A universal" exact="influenza" post="A vaccine based on the extracellular domain of the"/>
 <result pre="NgS.NachbagauerR.BalmasedaA.StadlbauerD.OjedaS.PatelM.et al.. (2019). Novel correlates of protection against pandemic H1N1" exact="influenza" post="A virus infection. Nat. Med.25, 962–967. 10.1038/s41591-019-0463-x31160818 OhH. L.AkerstromS.ShenS.BereczkyS.KarlbergH.KlingstromJ.et"/>
 <result pre="conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1" exact="influenza" post="viruses. J. Virol.84, 8275–8286. 10.1128/JVI.02593-0920519402 OhmitS. E.PetrieJ. G.CrossR. T.JohnsonE.MontoA."/>
 <result pre="10.1038/nrd.2017.24329326426 PardiN.ParkhouseK.KirkpatrickE.McMahonM.ZostS. J.MuiB. L.et al.. (2018b). Nucleoside-modified mRNA immunization elicits" exact="influenza" post="virus hemagglutinin stalk-specific antibodies. Nat. Commun.9:3361. 10.1038/s41467-018-05482-030135514 ParkJ. K.HanA.CzajkowskiL.ReedS.AthotaR.BristolT.et"/>
 <result pre="a correlate of protection in a healthy volunteer challenge with" exact="influenza" post="A/H1N1pdm Virus. MBio9:e02284–17. 10.1128/mBio.02284-1729362240 PaulS. S.MokC. K.MakT. M.NgO. W.AboagyeJ."/>
 <result pre="K.MakT. M.NgO. W.AboagyeJ. O.WohlboldT. J.et al.. (2017). A cross-clade H5N1" exact="influenza" post="A virus neutralizing monoclonal antibody binds to a novel"/>
 <result pre="I.MarstonH. D.EisingerR. W.BaltimoreD.FauciA. S. (2017). The pathway to a universal" exact="influenza" post="vaccine. Immunity47, 599–603. 10.1016/j.immuni.2017.09.00729045889 PeirisJ. S.HuiK. P.YenH. L. (2010)."/>
 <result pre="599–603. 10.1016/j.immuni.2017.09.00729045889 PeirisJ. S.HuiK. P.YenH. L. (2010). Host response to" exact="influenza" post="virus: protection versus immunopathology. Curr. Opin. Immunol.22, 475–481. 10.1016/j.coi.2010.06.00320594815"/>
 <result pre="conserved part of the viral M2 ectodomain cure and prevent" exact="influenza" post="A virus infection. Antiviral Res.141, 155–164. 10.1016/j.antiviral.2017.02.01628257797 PerezJ. T.PhamA."/>
 <result pre="T.PhamA. M.LoriniM. H.ChuaM. A.SteelJ.tenOeverB. R. (2009). MicroRNA-mediated species-specific attenuation of" exact="influenza" post="A virus. Nat. Biotechnol.27, 572–576. 10.1038/nbt.154219483680 PetschB.SchneeM.VogelA. B.LangeE.HoffmannB.VossD.et al.."/>
 <result pre="Protective efficacy of in vitro synthesized, specific mRNA vaccines against" exact="influenza" post="A virus infection. Nat. Biotechnol.30, 1210–1216. 10.1038/nbt.243623159882 PetukhovaN. V.GasanovaT."/>
 <result pre="V.et al.. (2013). Immunogenicity and protective efficacy of candidate universal" exact="influenza" post="A nanovaccines produced in plants by Tobacco mosaic virus-based"/>
 <result pre="PiepenbrinkM. S.NogalesA.BasuM.FucileC. F.LiesveldJ. L.KeeferM. C.et al.. (2019). Broad and protective" exact="influenza" post="B virus neuraminidase antibodies in humans after vaccination and"/>
 <result pre="PowellT. J.PengY.BerthoudT. K.BlaisM. E.LillieP. J.HillA. V.et al.. (2013). Examination of" exact="influenza" post="specific T cell responses after influenza virus challenge in"/>
 <result pre="al.. (2013). Examination of influenza specific T cell responses after" exact="influenza" post="virus challenge in individuals vaccinated with MVA-NP+M1 vaccine. PLoS"/>
 <result pre="vaccine. PLoS ONE8:e62778. 10.1371/journal.pone.006277823658773 PowellT. J.SilkJ. D.SharpsJ.FodorE.TownsendA. R. (2012). Pseudotyped" exact="influenza" post="A virus as a vaccine for the induction of"/>
 <result pre="antigens protects mice and ferrets against virulent H1N1 and H5N1" exact="influenza" post="A viruses. Vaccine27, 6512–6521. 10.1016/j.vaccine.2009.08.05319729082 RajaoD. S.ChenH.PerezD. R.SandbulteM. R.GaugerP."/>
 <result pre="RajaoD. S.ChenH.PerezD. R.SandbulteM. R.GaugerP. C.LovingC. L.et al.. (2016). Vaccine-associated enhanced" exact="respiratory disease" post="is influenced by haemagglutinin and neuraminidase in whole inactivated"/>
 <result pre="disease is influenced by haemagglutinin and neuraminidase in whole inactivated" exact="influenza" post="virus vaccines. J. Gen. Virol.97, 1489–1499. 10.1099/jgv.0.00046827031847 RajaoD. S.LovingC."/>
 <result pre="Influenza A virus hemagglutinin protein subunit vaccine elicits vaccine-associated enhanced" exact="respiratory disease" post="in pigs. Vaccine32, 5170–5176. 10.1016/j.vaccine.2014.07.05925077416 RavinN. V.BlokhinaE. A.KuprianovV. V.StepanovaL."/>
 <result pre="V.StepanovaL. A.ShaldjanA. A.KovalevaA. A.et al.. (2015). Development of a candidate" exact="influenza" post="vaccine based on virus-like particles displaying influenza M2e peptide"/>
 <result pre="of a candidate influenza vaccine based on virus-like particles displaying" exact="influenza" post="M2e peptide into the immunodominant loop region of hepatitis"/>
 <result pre="displaying influenza M2e peptide into the immunodominant loop region of" exact="hepatitis" post="B core antigen: Insertion of multiple copies of M2e"/>
 <result pre="cross protection in mice afforded by pandemic H1N1 live attenuated" exact="influenza" post="vaccine containing wild-type nucleoprotein. Biomed. Res. Int.2017:9359276. 10.1155/2017/935927628210631 Rosendahl"/>
 <result pre="K.CampsM. G.JacobiR. H.MouthaanJ.van DijkenH.van BeekJ.et al.. (2015). Synthetic long peptide" exact="influenza" post="vaccine containing conserved T and B cell epitopes reduces"/>
 <result pre="SagawaH.OhshimaA.KatoI.OkunoY.IsegawaY. (1996). The immunological activity of a deletion mutant of" exact="influenza" post="virus haemagglutinin lacking the globular region. J. Gen Virol.77"/>
 <result pre="10.1038/srep4504328344335 SarawarS.HattaY.WatanabeS.DiasP.NeumannG.KawaokaY.et al.. (2016). M2SR, a novel live single replication" exact="influenza" post="virus vaccine, provides effective heterosubtypic protection in mice. Vaccine34,"/>
 <result pre="L. (1969). The role of antineuraminidase antibody in immunity to" exact="influenza" post="virus infection. Bull World Health Organ.41, 647–650. 5309490 SchulmanJ."/>
 <result pre="Independent variation in nature of hemagglutinin and neuraminidase antigens of" exact="influenza" post="virus: distinctiveness of hemagglutinin antigen of Hong Kong-68 virus."/>
 <result pre="multimechanistic antibody targeting the receptor binding site potently cross-protects against" exact="influenza" post="B viruses. Sci. Transl. Med.9:eaam5752. 10.1126/scitranslmed.aam575229046433 SkowronskiD. M.De SerresG.CrowcroftN."/>
 <result pre="S.JanjuaN. Z.BoulianneN.HottesT. S.et al.. (2010). Association between the 2008–09 seasonal" exact="influenza" post="vaccine and pandemic H1N1 illness during Spring-Summer 2009: four"/>
 <result pre="chickens. Vaccine34, 678–686. 10.1016/j.vaccine.2015.11.07426691568 SridharS. (2016). Heterosubtypic T-cell immunity to" exact="influenza" post="in humans: challenges for universal T-cell influenza vaccines. Front."/>
 <result pre="T-cell immunity to influenza in humans: challenges for universal T-cell" exact="influenza" post="vaccines. Front. Immunol.7:195. 10.3389/fimmu.2016.0019527242800 SridharS.BrokstadK. A.CoxR. J. (2015). Influenza"/>
 <result pre="J. (2015). Influenza vaccination strategies: comparing inactivated and live attenuated" exact="influenza" post="vaccines. Vaccines3, 373–389. 10.3390/vaccines302037326343192 StechJ.GarnH.WegmannM.WagnerR.KlenkH. D. (2005). A new"/>
 <result pre="373–389. 10.3390/vaccines302037326343192 StechJ.GarnH.WegmannM.WagnerR.KlenkH. D. (2005). A new approach to an" exact="influenza" post="live vaccine: modification of the cleavage site of hemagglutinin."/>
 <result pre="MBio1:e00018–10. 10.1128/mBio.00018-1020689752 SuB.WurtzerS.Rameix-WeltiM.-A.DwyerD.van der WerfS.NaffakhN.et al.. (2010). Enhancement of the" exact="influenza" post="A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by"/>
 <result pre="SubbramanianR. A.BashaS.ShataM. T.BradyR. C.BernsteinD. I. (2010). Pandemic and seasonal H1N1" exact="influenza" post="hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination."/>
 <result pre="seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal" exact="influenza" post="vaccination. Vaccine28, 8258–8267. 10.1016/j.vaccine.2010.10.07721050903 SuiJ.HwangW. C.PerezS.WeiG.AirdD.ChenL. M.et al.. (2009)."/>
 <result pre="and functional bases for broad-spectrum neutralization of avian and human" exact="influenza" post="A viruses. Nat. Struct. Mol. Biol.16, 265–273. 10.1038/nsmb.156619234466 SunW.KirkpatrickE.ErmlerM.NachbagauerR.BroeckerF.KrammerF.et"/>
 <result pre="Struct. Mol. Biol.16, 265–273. 10.1038/nsmb.156619234466 SunW.KirkpatrickE.ErmlerM.NachbagauerR.BroeckerF.KrammerF.et al.. (2019). Development of" exact="influenza" post="B universal vaccine candidates using the &quot;mosaic�? hemagglutinin approach."/>
 <result pre="(2015). High copy numbers and N terminal insertion position of" exact="influenza" post="A M2E fused with hepatitis B core antigen enhanced"/>
 <result pre="N terminal insertion position of influenza A M2E fused with" exact="hepatitis" post="B core antigen enhanced immunogenicity. Biosci. Trends9, 221–227. 10.5582/bst.2015.0106026355223"/>
 <result pre="monoclonal antibody that targets the fusion domain of group 2" exact="influenza" post="A virus hemagglutinin. J. Virol.88, 13580–13592. 10.1128/JVI.02289-1425210195 TanG. S.LeonP."/>
 <result pre="(2016). Broadly-reactive neutralizing and non-neutralizing antibodies directed against the H7" exact="influenza" post="virus hemagglutinin reveal divergent mechanisms of protection. PLoS Pathog.12:e1005578."/>
 <result pre="mechanisms of protection. PLoS Pathog.12:e1005578. 10.1371/journal.ppat.100557827081859 TanJ.Asthagiri ArunkumarG.KrammerF. (2018). Universal" exact="influenza" post="virus vaccines and therapeutics: where do we stand with"/>
 <result pre="influenza virus vaccines and therapeutics: where do we stand with" exact="influenza" post="B virus?Curr. Opin. Immunol.53, 45–50. 10.1016/j.coi.2018.04.00229677684 TerajimaM.BabonJ. A.CoM. D.EnnisF."/>
 <result pre="(2013). Cross-reactive human B cell and T cell epitopes between" exact="influenza" post="A and B viruses. Virol. J.10:244. 10.1186/1743-422X-10-24423886073 TerajimaM.CruzJ.CoM. D.LeeJ."/>
 <result pre="J.10:244. 10.1186/1743-422X-10-24423886073 TerajimaM.CruzJ.CoM. D.LeeJ. H.KaurK.WrammertJ.et al.. (2011). Complement-dependent lysis of" exact="influenza" post="a virus-infected cells by broadly cross-reactive human monoclonal antibodies."/>
 <result pre="A.LiuT.YeZ.et al.. (2007). Matrix protein 2 vaccination and protection against" exact="influenza" post="viruses, including subtype H5N1. Emerg. Infect. Dis.13, 426–435. 10.3201/eid1303.06112517552096"/>
 <result pre="V.BlokhinaE. A.PotapchukM. V.KorotkovA. V.et al.. (2015). Development of a candidate" exact="influenza" post="vaccine based on virus-like particles displaying influenza M2e peptide"/>
 <result pre="of a candidate influenza vaccine based on virus-like particles displaying" exact="influenza" post="M2e peptide into the immunodominant region of hepatitis B"/>
 <result pre="particles displaying influenza M2e peptide into the immunodominant region of" exact="hepatitis" post="B core antigen: broad protective efficacy of particles carrying"/>
 <result pre="(2018). Combination of M2e peptide with stalk HA epitopes of" exact="influenza" post="A virus enhances protective properties of recombinant vaccine. PLoS"/>
 <result pre="vaccine. PLoS ONE13:e0201429. 10.1371/journal.pone.020142930138320 UiH.YamayoshiS.UrakiR.KisoM.OishiK.MurakamiS.et al.. (2017). Evaluation of seasonal" exact="influenza" post="vaccines for H1N1pdm09 and type B viruses based on"/>
 <result pre="J.ParkerS. E.RhodesG. H.FelgnerP. L.DwarkiV. J.et al.. (1993). Heterologous protection against" exact="influenza" post="by injection of DNA encoding a viral protein. Science259,"/>
 <result pre="al.. (2013). A novel bivalent vaccine based on a PB2-knockout" exact="influenza" post="virus protects mice from pandemic H1N1 and highly pathogenic"/>
 <result pre="virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing" exact="influenza" post="B lineage. J. Gen Virol.96, 2061–2073. 10.1099/vir.0.00015625900135 van de"/>
 <result pre="E.et al.. (2014). Human cytotoxic T lymphocytes directed to seasonal" exact="influenza" post="A viruses cross-react with the newly emerging H7N9 virus."/>
 <result pre="J. Virol.88, 1684–1693. 10.1128/JVI.02843-1324257602 VictorS. T.WatanabeS.KatsuraH.OzawaM.KawaokaY. (2012). A replication-incompetent PB2-knockout" exact="influenza" post="A virus vaccine vector. J. Virol.86, 4123–4128. 10.1128/JVI.06232-1122301144 VigilA.EstellesA.KauvarL."/>
 <result pre="(2018). Native human monoclonal antibodies with potent cross-lineage neutralization of" exact="influenza" post="B viruses. Antimicrob. Agents Chemother.62:e02269–e02217. 10.1128/AAC.02269-1729507069 WalzL.KaysS. K.ZimmerG.von MesslingV."/>
 <result pre="MesslingV. (2018). Neuraminidase-inhibiting antibody titers correlate with protection from heterologous" exact="influenza" post="virus strains of the same neuraminidase subtype. J. Virol.92:e01006–e01018."/>
 <result pre="epitopes in seasonal and pandemic H1N1 as well as H5N1" exact="influenza" post="viruses. J. Virol.87, 9290–9300. 10.1128/JVI.01203-1323785204 WangR.SongA.LevinJ.DennisD.ZhangN. J.YoshidaH.et al.. (2008)."/>
 <result pre="(2008). Therapeutic potential of a fully human monoclonal antibody against" exact="influenza" post="A virus M2 protein. Antiviral Res.80, 168–177. 10.1016/j.antiviral.2008.06.00218598723 WangS.RenH.JiangW.ChenH.HuH.ChenZ.et"/>
 <result pre="requirement of Fc-Fcγ receptor interactions for in vivo protection against" exact="influenza" post="viruses by two pan-H5 hemagglutinin antibodies. J. Virol.91, e02065–e02016."/>
 <result pre="M1 proteins as immunogens in DNA- and vaccinia virus-based universal" exact="influenza" post="A virus vaccines in mice. Clin. Vaccine Immunol.22, 618–630."/>
 <result pre="Clin. Vaccine Immunol.22, 618–630. 10.1128/CVI.00091-1525834017 WangY.DengL.KangS. M.WangB. Z. (2018a). Universal" exact="influenza" post="vaccines: from viruses to nanoparticles. Exp. Rev. Vaccines17, 967–976."/>
 <result pre="10.1038/s41467-018-03243-729483513 WeaverE. A.RubrumA. M.WebbyR. J.BarryM. A. (2011). Protection against divergent" exact="influenza" post="H1N1 virus by a centralized influenza hemagglutinin. PLoS ONE6:e18314."/>
 <result pre="(2011). Protection against divergent influenza H1N1 virus by a centralized" exact="influenza" post="hemagglutinin. PLoS ONE6:e18314. 10.1371/journal.pone.001831421464940 WhittleJ. R.ZhangR.KhuranaS.KingL. R.ManischewitzJ.GoldingH.et al.. (2011)."/>
 <result pre="Broadly neutralizing human antibody that recognizes the receptor-binding pocket of" exact="influenza" post="virus hemagglutinin. Proc. Natl. Acad. Sci. U.S.A.108, 14216–14221. 10.1073/pnas.111149710821825125"/>
 <result pre="14216–14221. 10.1073/pnas.111149710821825125 WinarskiK. L.TangJ.KlenowL.LeeJ.CoyleE. M.ManischewitzJ.et al.. (2019). Antibody-dependent enhancement of" exact="influenza" post="disease promoted by increase in hemagglutinin stem flexibility and"/>
 <result pre="Hemagglutinin stalk- and neuraminidase-specific monoclonal antibodies protect against lethal H10N8" exact="influenza" post="virus infection in mice. J. Virol.90, 851–861. 10.1128/JVI.02275-1526512088 WohlboldT."/>
 <result pre="(2014). In the shadow of hemagglutinin: a growing interest in" exact="influenza" post="viral neuraminidase and its role as a vaccine antigen."/>
 <result pre="recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against" exact="influenza" post="virus infection in mice. MBio6:e0255610.1128/mBio.02556-1425759506 WohlboldT. J.PodolskyK. A.ChromikovaV.KirkpatrickE.FalconieriV.MeadeP.et al.."/>
 <result pre="J.PodolskyK. A.ChromikovaV.KirkpatrickE.FalconieriV.MeadeP.et al.. (2017). Broadly protective murine monoclonal antibodies against" exact="influenza" post="B virus target highly conserved neuraminidase epitopes. Nat. Microbiol.2,"/>
 <result pre="YangC.SkienaS.FutcherB.MuellerS.WimmerE. (2013). Deliberate reduction of hemagglutinin and neuraminidase expression of" exact="influenza" post="virus leads to an ultraprotective live vaccine in mice."/>
 <result pre="YangX.SteukersL.ForierK.XiongR.BraeckmansK.Van ReethK.et al.. (2014). A beneficiary role for neuraminidase in" exact="influenza" post="virus penetration through the respiratory mucus. PLoS ONE9:e110026. 10.1371/journal.pone.011002625333824"/>
 <result pre="C.McTamneyP. M.WeiC. J.KanekiyoM.KongW. P.et al.. (2015). Hemagglutinin-stem nanoparticles generate heterosubtypic" exact="influenza" post="protection. Nat. Med. 21, 1065–1070. 10.1038/nm.392726301691 ZhangG. G.LiD. X.ZhangH."/>
 <result pre="adjuvant LTB induces T cell dependent, cross-clade protection against H5N1" exact="influenza" post="virus in mice. Vaccine34, 622–629. 10.1016/j.vaccine.2015.12.03926724200 ZhengZ.PaulS. S.MoX.YuanY. A.TanY."/>
 <result pre="J. (2018). The vestigial esterase domain of haemagglutinin of H5N1" exact="avian influenza" post="A virus: antigenicity and contribution to viral pathogenesis. Vaccines6:53."/>
 <result pre="(2018). The vestigial esterase domain of haemagglutinin of H5N1 avian" exact="influenza" post="A virus: antigenicity and contribution to viral pathogenesis. Vaccines6:53."/>
</results>
